Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (11-20 of 181) with videos related to

Pageof 19
Sort By:
Leukemia Research|November 26, 2015
Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLLJoshua Kellner, William Wierda, Elizabeth Shpall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonucleaseAlma Zecevic, Deepa Sampath, Brett Ewald, et al.
Cancer|March 13, 2010
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrenceStefan Faderl, Alessandra Ferrajoli, William Wierda, et al.
Leukemia Research|August 4, 2009
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 YearsStefan Faderl, William Wierda, Susan O'Brien, et al.
Hematology/Oncology and Stem Cell Therapy|June 29, 2016
Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumabPunit Jain, Rashmi Kanagal-Shamanna, William Wierda, et al.
British Journal of Haematology|November 9, 2018
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopeniaShilpa Paul, Nitin Jain, Alessandra Ferrajoli, et al.
Cancer|July 29, 2009
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemiaNitin Jain, William Wierda, Alessandra Ferrajoli, et al.
Current Hematologic Malignancy Reports|December 11, 2012
CARs in chronic lymphocytic leukemia -- ready to driveChitra Hosing, Partow Kebriaei, William Wierda, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspectiveNina Shah, Katy Rezvani, Chitra Hosing, et al.
Leukemia & Lymphoma|July 2, 2013
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemiaPaolo Strati, Alessandra Ferrajoli, Susan Lerner, et al.
Pageof 19

Showing results (11-20 of 181) with videos related to

Sort By:
Pageof 19
Leukemia Research|November 26, 2015
Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLLJoshua Kellner, William Wierda, Elizabeth Shpall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonucleaseAlma Zecevic, Deepa Sampath, Brett Ewald, et al.
Cancer|March 13, 2010
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrenceStefan Faderl, Alessandra Ferrajoli, William Wierda, et al.
Leukemia Research|August 4, 2009
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 YearsStefan Faderl, William Wierda, Susan O'Brien, et al.
Hematology/Oncology and Stem Cell Therapy|June 29, 2016
Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumabPunit Jain, Rashmi Kanagal-Shamanna, William Wierda, et al.
British Journal of Haematology|November 9, 2018
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopeniaShilpa Paul, Nitin Jain, Alessandra Ferrajoli, et al.
Cancer|July 29, 2009
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemiaNitin Jain, William Wierda, Alessandra Ferrajoli, et al.
Current Hematologic Malignancy Reports|December 11, 2012
CARs in chronic lymphocytic leukemia -- ready to driveChitra Hosing, Partow Kebriaei, William Wierda, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspectiveNina Shah, Katy Rezvani, Chitra Hosing, et al.
Leukemia & Lymphoma|July 2, 2013
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemiaPaolo Strati, Alessandra Ferrajoli, Susan Lerner, et al.
Pageof 19